Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2020

View Archived Issues

iPSCs find best therapy for Best disease

Terns and Hansoh enter collaboration and license agreement for TRN-000632 in Greater China

Proof of concept seen with CAR T cells targeting chondroitin sulfate for treating bladder cancer

Bayer presents promising preclinical and phase I data for BAY-2433334

Novel mouse model of AAA with intraluminal thrombus

Kyorin Pharmaceutical discloses new 15-hydroxyprostaglandin dehydrogenase inhibitors

New MGAT2 inhibitors discovered at Shionogi

Incyte synthesizes new STING receptor agonists

Lilly discovers interleukin-17 receptor A antagonists

Genetic variant combination in MPIG6B and SH2B3 genes leads to myelofibrosis and thrombocytopenia

Astrogen identifies new serine derivatives

Screening in serum yields potential antibiotics against drug-resistant K. pneumoniae

Positive topline data presented from phase IIa ACTION study of DMX-200 in FSGS

Apogenix receives regulatory approval in Russia for phase II study of asunercept in COVID-19

Arrowhead initiates phase II study of AMG-890

First patient dosed in phase I/II study of RP-3500

Constant Therapeutics initiates phase II study of TXA-127 for COVID-19

Enterome begins clinical evaluation of cancer multipeptide therapeutic vaccine EO-2401

Phase I trial evaluates IBS therapy SMP-100 in healthy volunteers

INSPIRE trial of rigosertib reaches required survival events for data analysis

Noxopharm advances Veyonda for prostate cancer and COVID-19

ONC-392 moves into first-in-human study in advanced solid tumors and NSCLC

AL-001 normalizes progranulin levels in patients with GRN gene-mutation frontotemporal dementia